Molecular Characteristics of Leptomeningeal Melanoma Metastases Identified
By LabMedica International staff writers Posted on 20 Jan 2020 |
Image: Histopathology of Leptomeningeal Melanoma Metastases: tumor cell clusters in the subarachnoid space in a brain biopsy (Photo courtesy of selbst).
Patients with advanced melanoma who develop metastases in the leptomeninges, the fluid filled membranes surrounding the brain and spinal cord, have an extremely poor prognosis. Most patients only survive for eight to 10 weeks after diagnosis.
Cancer development and progression are highly regulated by intricate interactions between cancer cells and the surrounding environment. Melanoma cells that invade and metastasize into the leptomeninges interact with the surrounding cerebrospinal fluid. One reason for the poor prognosis is that very little information is known about the molecular development of leptomeningeal melanoma metastases (LMM), making it difficult to develop effective therapies.
Molecular oncologists and their colleagues at the Moffitt Cancer Center (Tampa, FL, USA) collected a total of 45 serial cerebrospinal fluid (CSF) samples from 16 patients, eight of these with confirmed LMM. Of those with LMM, seven had poor survival (<4 months) and one was an extraordinary responder (still alive with survival >35 months). CSF samples were analyzed by mass spectrometry and incubated with melanoma cells that were subjected to RNA-Seq analysis. Functional assays were performed to validate the pathways identified.
The scientists reported that mass spectrometry analyses showed the CSF of most LMM patients to be enriched for pathways involved in innate immunity, protease-mediated damage, and insulin-like growth factor (IGF)-related signaling. All of these were anti-correlated in the extraordinary responder. The most commonly altered protein was Transforming growth factor beta 1 (TGF-β1). Interestingly, the one patient who had an extraordinary response to treatment displayed high levels of these proteins at baseline, but expression levels decreased as the patient responded to treatment.
RNA-Seq analysis showed CSF to induce PI3K/AKT, integrin, B-cell activation, S-phase entry, TNFR2, TGF-band oxidative stress responses in the melanoma cells. ELISA assays confirmed that TGF-β expression increased in the CSF of patients progressing with LMM. CSF from poorly responding patients conferred tolerance to BRAF inhibitor therapy in apoptosis assays. However, the protein expression patterns in the remaining LMM patients who had poor responses to treatment were high at baseline and remained high throughout treatment and disease progression.
The findings demonstrate that the CSF from LMM patients who did not respond to treatment promoted survival of melanoma cells, while the cerebrospinal fluid from the extraordinary responder did not promote survival. These observations suggest that molecules exist within the cerebrospinal fluid that can stimulate melanoma cell survival and prevent cell death.
The authors concluded that their analyses identified proteomic/transcriptional signatures in the CSF of patients who succumbed to LMM. They further showed that the CSF from LMM patients has the potential to modulate BRAF inhibitor responses and may contribute to drug resistance. The study was published on January 10, 2020 in the journal Clinical Cancer Research.
Related Links:
Moffitt Cancer Center
Cancer development and progression are highly regulated by intricate interactions between cancer cells and the surrounding environment. Melanoma cells that invade and metastasize into the leptomeninges interact with the surrounding cerebrospinal fluid. One reason for the poor prognosis is that very little information is known about the molecular development of leptomeningeal melanoma metastases (LMM), making it difficult to develop effective therapies.
Molecular oncologists and their colleagues at the Moffitt Cancer Center (Tampa, FL, USA) collected a total of 45 serial cerebrospinal fluid (CSF) samples from 16 patients, eight of these with confirmed LMM. Of those with LMM, seven had poor survival (<4 months) and one was an extraordinary responder (still alive with survival >35 months). CSF samples were analyzed by mass spectrometry and incubated with melanoma cells that were subjected to RNA-Seq analysis. Functional assays were performed to validate the pathways identified.
The scientists reported that mass spectrometry analyses showed the CSF of most LMM patients to be enriched for pathways involved in innate immunity, protease-mediated damage, and insulin-like growth factor (IGF)-related signaling. All of these were anti-correlated in the extraordinary responder. The most commonly altered protein was Transforming growth factor beta 1 (TGF-β1). Interestingly, the one patient who had an extraordinary response to treatment displayed high levels of these proteins at baseline, but expression levels decreased as the patient responded to treatment.
RNA-Seq analysis showed CSF to induce PI3K/AKT, integrin, B-cell activation, S-phase entry, TNFR2, TGF-band oxidative stress responses in the melanoma cells. ELISA assays confirmed that TGF-β expression increased in the CSF of patients progressing with LMM. CSF from poorly responding patients conferred tolerance to BRAF inhibitor therapy in apoptosis assays. However, the protein expression patterns in the remaining LMM patients who had poor responses to treatment were high at baseline and remained high throughout treatment and disease progression.
The findings demonstrate that the CSF from LMM patients who did not respond to treatment promoted survival of melanoma cells, while the cerebrospinal fluid from the extraordinary responder did not promote survival. These observations suggest that molecules exist within the cerebrospinal fluid that can stimulate melanoma cell survival and prevent cell death.
The authors concluded that their analyses identified proteomic/transcriptional signatures in the CSF of patients who succumbed to LMM. They further showed that the CSF from LMM patients has the potential to modulate BRAF inhibitor responses and may contribute to drug resistance. The study was published on January 10, 2020 in the journal Clinical Cancer Research.
Related Links:
Moffitt Cancer Center
Latest Pathology News
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes